Doxylamine succinate
This article was originally published in The Tan Sheet
Executive Summary
September 1994 issue of FDA Consumer outlines the regulatory history of the nighttime sleep-aid. The article was written at the recommendation of FDA's Nonprescription Drugs Advisory Committee at a July 1993 meeting to inform consumers of the tumorigenicity potential of the antihistamine/sleep-aid in rodents. The advisory committee suggested the article in lieu of requiring a label warning ("The Tan Sheet" July 5, 1993, p. 5). FDA's Pulmonary-Allergy Drugs Advisory Committee earlier recommended a warning label. The article notes that FDA conducted a tumorigenicity study in rats and mice that was inconclusive
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning